Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2001 Sep;98(1):103-8.
doi: 10.1016/s0301-2115(00)00562-5.

P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression

P J Coronado  1 , J A Vidart, J A Lopez-asenjo, M Fasero, V Furio-bacete, J Magrina, M Escudero
Affiliations
Comparative Study

P53 overexpression predicts endometrial carcinoma recurrence better than HER-2/neu overexpression

P J Coronado et al. Eur J Obstet Gynecol Reprod Biol. 2001 Sep.

Abstract

Objective: to investigate the prognostic value of p53 and HER-2/neu overexpression in endometrial cancer.

Study design: p53 and HER-2/neu immunostaining was performed in 114 paraffin-embedded specimens of endometrial cancer diagnosed and treated between 1990 and 1997. Nuclear p53 and membrane HER-2/neu immunostaining were used.

Results: p53 and HER-2/neu overexpression was observed in 17 cases (14.9%) and in 19 cases (16.7%), respectively. In univariate analysis p53 (P<0.001) and HER-2/neu (P=0.018) overexpression had a positive correlation with a high risk of recurrence. In multivariate analysis, age (P<0.001), FIGO stage (P<0.001), differentiation (P=0.013), non-endometrioid subtypes (P<0.001) and p53 overexpression (P<0.001), but not HER-2/neu overexpression, were independent prognostic indicators of recurrence. Simultaneous p53 and HER-2/neu overexpression made worse the prognostic (P<0.001).

Conclusions: p53 overexpression was an independent predictor of recurrent disease in endometrial cancer. HER-2/neu overexpression had a more limited effect but enhance the effect of p53.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources